The Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced Thursday, Jan. 4, the publication of appropriate use criteria (AUC) for somatostatin receptor PET imaging in neuroendocrine tumors.

To develop this AUC, which “addresses several clinical scenarios for neuroendocrine tumors,” SNMMI says it collaborated with several other groups, including the American College of Radiology, the European Association of Nuclear Medicine, the European Neuroendocrine Tumor Society, the American Gastroenterological Association, the American Society of Clinical Oncology and many others.

SNMMI also established a Somatostatin Receptor PET Imaging in Neuroendocrine Tumors Workgroup, putting representatives from several specialties together to “review the scientific literature and develop consensus recommendations.”

More information about the AUC can be found on the SNMMI website. Information specifically about how the AUC was developed is available here.

According to its statement, SNMMI members are also presently developing AUC for the following subjects: gastrointestinal transit, infection imaging, PET myocardial perfusion imaging, prostate cancer imaging, somatostatin imaging, and thyroid imaging and therapy.